The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Provision of signed and dated informed consent form
* Male or female, aged 18-70 years
* In good general health as evidenced by medical history
* Peripheral night blood W. bancrofti Mf levels ≥40 Mf/mL
* No history of taking antifilarial medications in past 12 months
* Resident of the study area with no plans to change residence in the next 36 months
* For women of childbearing potential, willing to use appropriate method of contraception for one month following each treatment
Exclusion Criteria:
* Pregnancy or currently breastfeeding
* Known allergic reactions to any of the study medications
* Evidence of severe or systemic comorbidities (aside from features of filarial disease), as judged by the principal investigator
* Baseline biochemical abnormalities, as indicated by AST, ALT, or creatinine \> 2 times the upper limit of normal
* Evidence of urinary tract infection as indicated by 3+ nitrites on dipstick (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic kidney disease as indicated by 3+ protein or 3+ blood on urine dipstick exam
* Hgb \< 7 gm/dL (any such individuals will be referred to the local health center for evaluation and treatment)
* Positive skin snip for onchocerciasis